Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cilengitide for Recurrent Glioblastoma
NCT00112866Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Jan 2005
- Primary completion
- Dec 2008
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of cilengitide in glioblastoma multiforme (GBM), sponsored by National Cancer Institute. Started Jan 2005; status: terminated.
02
Drugs
cilengitide
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00112866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00112866.